Merck Investors Can't Use Vioxx News Report In Fraud MDL

Law360, New York (May 30, 2013, 4:12 PM EDT) -- A New Jersey federal judge on Wednesday allowed a class of Merck & Co. Inc. investors to tweak its securities fraud suit against the drugmaker for a sixth time but barred the inclusion of a 2004 news article, finding it didn't provide any new information about Merck's alleged knowledge of the possible risks of its painkiller Vioxx.

The opinion is a tempered victory for plaintiffs, who can now amend their complaint to include a 2000 statement they say misled shareholders to think a small group of...
To view the full article, register now.